Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

10.49
+0.13001.25%
Post-market: 10.540.0500+0.48%19:30 EDT
Volume:1.52M
Turnover:15.77M
Market Cap:2.30B
PE:-7.42
High:10.54
Open:10.30
Low:10.13
Close:10.36
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:0.89
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:4.42
PE(LYR):-7.39

Loading ...

Ocular Therapeutix (OCUL) Could Be 60% Below Fair Value As Axpaxli Story Builds

Simply Wall St.
·
Aug 25

Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset

TIPRANKS
·
Aug 17

Ocular Therapeutix rises 10.4%

TIPRANKS
·
Aug 17

Rival Ocular Therapeutix Shares up 8%

THOMSON REUTERS
·
Aug 17

Ocular Therapeutix Shares up 12.7% Premarket After Rival EyePoint's Eye Drug Misses Main Goal in Late-Stage Trial

THOMSON REUTERS
·
Aug 17

Ocular Therapeutix Grants New SVP Beth Rada Options for 85,000 Shares, 28,000 RSUs Under Inducement Plan

Reuters
·
Aug 14

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 14

Ocular Therapeutix Grants Inducement Awards to New Hires, Including Options Priced at $8.4 Per Share

Reuters
·
Aug 08

Ocular Therapeutix™ Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 08

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 08

Tarsus Pharmaceuticals Q2 Sales Beat Estimates, Lifts 2026 Xdemvy Sales Outlook

Reuters
·
Aug 06

Viridian Therapeutics Q2 Net Loss Widens as Lumvoa Launch Lifts Costs

Reuters
·
Aug 06

RxSight Q2 Adjusted Loss Beats Estimates; Withdraws 2026 Guidance

Reuters
·
Aug 06

Sight Sciences Q2 Revenue Rises 20%, Beats Estimates

Reuters
·
Aug 06

Canada's Kits Eyecare Q2 Revenue Slightly Beats on Glasses Segment Growth

Reuters
·
Aug 05

EyePoint Pharmaceuticals Q2 Revenue Drops on Lower License Income

Reuters
·
Aug 05

Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says

MT Newswires Live
·
Aug 04

Palvella Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 04

Ocular Therapeutix Faces Governance and Perception Risks from Insider Equity Compensation and Trading Practices

TIPRANKS
·
Aug 04

Stoke Therapeutics Q2 Revenue Falls 33% on Lower Collaboration, Licensing Income

Reuters
·
Aug 04